Global Non-Alcoholic Steatohepatitis Industry: Key Statistics and Insights in 2024-2032

Summary:

• The global non-alcoholic steatohepatitis market size reached USD 1.6 Billion in 2023.
• The market is expected to reach USD 11.5 Billion by 2032, exhibiting a growth rate (CAGR) of 24.18% during 2024-2032.
• North America leads the market, accounting for the largest non-alcoholic steatohepatitis market share.
• Vitamin E and pioglitazone account for the majority of the market share in the drug type segment as they help reduce liver inflammation and improve liver histology. 
• Obesity holds the largest share in the non-alcoholic steatohepatitis industry.
• Retail pharmacy remain a dominant segment in the market because of their ability to provide enhanced care to individuals.
• Clinics represents the leading end user segment.
• The rising prevalence of obesity and diabetes is a primary driver of the non-alcoholic steatohepatitis market.
• The increasing awareness and diagnosis and research and development (R&D) activities are reshaping the non-alcoholic steatohepatitis market.

Industry Trends and Drivers:

• Growing Prevalence of Obesity and Diabetes:

The increasing prevalence of obesity and diabetes among the masses across the globe is catalyzing the demand for non-alcoholic steatohepatitis (NASH). These conditions are closely linked to metabolic syndrome, which includes non-alcoholic fatty liver disease (NAFLD) and NASH as major components. Excess fat accumulation in the liver, particularly on account of obesity, leads to inflammation and damage characteristic of NASH. As the incidence of obesity and diabetes escalates, so does the demand for effective NASH treatment options. The healthcare sector is prioritizing these conditions, leading to increased awareness, research funding, and healthcare interventions focused on managing NASH, thereby driving the market forward.      

• Rising Awareness and Diagnosis:

The increasing awareness among individuals and healthcare professionals about NASH is supporting the market growth. This awareness is resulting in improved diagnosis and treatment rates among individuals. Enhanced understanding of the disease, its risk factors, and its potential complications is leading to better screening practices and greater emphasis on early detection. Advanced diagnostic techniques, such as non-invasive imaging technologies and specific biomarkers, are now employed to identify NASH more accurately. This growing recognition enables timely interventions, which can significantly improve patient outcomes. Moreover, as awareness spreads, patients are more likely to seek medical advice and undergo screening, further increasing diagnosed cases of NASH.    

• Research and Development (R&D) Activities: 

The NASH market is experiencing robust growth due to increased research and development (R&D) efforts from pharmaceutical and biotechnology companies. With no approved pharmacological treatments specifically targeting NASH, there is a significant unmet medical need driving innovation. Many companies are investing heavily in (R&D) activities to develop novel therapies, such as anti-fibrotic agents, metabolic modulators, and liver-targeted treatments. Clinical trials are proliferating, exploring various drug mechanisms and combinations that can effectively address the disease's underlying causes. Additionally, partnerships and collaborations between academia, research institutions, and industry players are fostering a rich environment for innovation. Regulatory support for expedited approval processes further incentivizes R&D in this field.

Grab a sample PDF of this report: https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market/requestsample

Non-Alcoholic Steatohepatitis Market Report Segmentation:

Breakup By Sales Channel:

• Hospital Pharmacy
• Online Providers
• Retail Pharmacy

Retail pharmacy represents the majority of shares due to the easy availability of the product.

Breakup By End User:

• Hospitals
• Clinics
• Homecare Settings

Clinics hold the majority of shares because of their ability to provide enhanced care to individuals.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America enjoys the leading position owing to a large market for non-alcoholic steatohepatitis driven by favorable government initiatives.

Top Non-Alcoholic Steatohepatitis Market Leaders:

The non-alcoholic steatohepatitis market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• Algernon Pharmaceuticals
• Galmed Pharmaceuticals Ltd
• Intercept Pharmaceuticals Inc.
• Zydus Lifesciences Limited

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145